Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. reports developments as a clinical-stage biotechnology company advancing non-viral DNA technologies for immunotherapy and vaccines. Its lead candidate, IMNN-001, is a DNA-based interleukin-12 immunotherapy being developed for localized treatment of newly diagnosed advanced ovarian cancer through the OVATION clinical program.
Company news commonly covers clinical data from OVATION studies, Phase 3 development activity, financial results and business updates, and portfolio work around the TheraPlas platform for cytokine and therapeutic-protein delivery and the PlaCCine platform for viral-antigen delivery. Updates also include capital discipline, organization changes, and presentations of translational or proof-of-concept data.
IMUNON (Nasdaq: IMNN) announced oral presentations of PlaCCine® DNA vaccine proof-of-concept data and IMNN-101 clinical results at two vaccine conferences: Oct 23, 2025 (International Vaccines Congress, Orlando) and Nov 6, 2025 (International Conference on Vaccine Research and Development, Boston).
IMNN reported positive six-month Phase 1 data showing better durability versus mRNA after a single dose targeting SARS-CoV-2 Omicron XBB1.5, with up to a 3-fold median increase in serum neutralizing antibody titers at six months and stronger responses in the 2.0 mg and 1.0 mg cohorts. IMNN-101 was safe and well tolerated with no serious adverse effects. The company is seeking strategic partners to advance PlaCCine commercialization, highlighting durability, temperature stability, and scalable manufacturing.
IMUNON (Nasdaq: IMNN) will present a trials-in-progress poster on its pivotal Phase 3 OVATION 3 study of IMNN-001 at the European Society for Medical Oncology (ESMO) Congress, October 17–21, 2025 in Berlin.
IMNN-001 is an IL-12 DNA plasmid delivered in a nanoparticle to elicit local tumor immune responses. The company announced the first patient treated in July 2025, has activated 4 sites, and is considering up to 46 additional sites to accelerate enrollment. The poster (No. 1234eTiP) will be presented by Dr. Premal H. Thaker and posted on IMUNON’s Scientific Presentations page after the conference.
IMUNON (NASDAQ: IMNN) presented promising new translational data from its Phase 2 OVATION 2 Study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The study, involving 112 participants, demonstrated significant improvements in the tumor micro-environment (TME) through the local administration of IL-12 immunotherapy.
Key findings showed a positive TME shift in the majority of participants, with 50-80% of samples showing increased anti-tumor cells and 65-80% showing decreased immunosuppressive markers. The therapy effectively transformed "cold" tumors to "hot" by activating both innate and adaptive immune systems, while maintaining a favorable safety profile.
The company has initiated its pivotal Phase 3 OVATION 3 Study with four active trial sites currently enrolling patients.
IMUNON (NASDAQ: IMNN) announced it will present new translational data from its Phase 2 OVATION 2 Study of IMNN-001 at the AACR Special Conference in Cancer Research. IMNN-001 is a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer currently in Phase 3 development.
The therapy utilizes IMUNON's TheraPlas® technology platform, incorporating an IL-12 DNA plasmid vector into a nanoparticle delivery system. It has demonstrated clinical effectiveness in advanced ovarian cancer, showing benefits in both progression-free survival and overall survival when combined with standard chemotherapy.
The presentation, titled "IMNN-001, an IL-12 gene therapy, added to Neo/Adjuvant chemotherapy safely turns the tumor microenvironment cold-to-hot in newly diagnosed epithelial ovarian cancer (EOC)," will be delivered by Dr. Douglas V. Faller, Chief Medical Officer, on September 20, 2025.
IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York.
The company will provide a pre-recorded presentation that will be available on demand starting September 5, 2025, at 7:00 a.m. ET. IMUNON's management team will conduct in-person one-on-one meetings with investors from September 8-10, 2025. The presentation webcast will remain accessible for 90 days through the company's website.
IMUNON (Nasdaq: IMNN) has successfully regained compliance with Nasdaq's minimum bid price listing requirement, ensuring continued trading on The Nasdaq Capital Market. The company recently distributed a 15% stock dividend to shareholders of record as of August 7, 2025.
The announcement comes amid positive developments in IMUNON's clinical pipeline, including successful Phase 2 OVATION 2 trial results for IMNN-001, their DNA-based immunotherapy for advanced ovarian cancer treatment. The company has initiated the Phase 3 OVATION 3 trial in North America while advancing their TheraPlas® technology platform.
IMUNON (NASDAQ: IMNN) provided key updates from its Q2 2025 conference call, highlighting significant progress in its Phase 3 OVATION 3 trial for IMNN-001 in advanced ovarian cancer. The company has successfully enrolled and treated its first patient, achieving a rapid launch in just 15 weeks compared to the industry average of 28 weeks.
The company announced a 15% stock dividend for shareholders of record as of August 7, 2025. IMUNON has strengthened its financial position by raising over $3 million through warrant exercises and ATM sales. The company expects to meet Nasdaq's compliance requirements, including the Bid Price requirement, by August 8, 2025.
The Phase 3 trial features a flexible enrollment strategy starting with 250 HRD-positive patients, reducing costs by approximately 40%, with potential expansion to 500 patients. The company maintains efficient in-house manufacturing for IMNN-001, significantly reducing costs compared to outsourcing.
IMUNON (NASDAQ: IMNN) reported Q2 2025 financial results and significant progress in its clinical programs. The company announced a 15% stock dividend and dosed the first patient in its Phase 3 OVATION 3 Study of IMNN-001 for advanced ovarian cancer.
Q2 2025 financial highlights include a net loss of $2.7 million ($2.15 per share), improved from $4.8 million loss in Q2 2024. Operating expenses decreased 45% to $2.8 million. Cash position stands at $4.7 million, with additional $3.1 million raised in July 2025.
Key developments include positive Phase 2 OVATION 2 Study data showing 13-month median OS improvement, successful completion of a $9.75 million private placement, and a Nasdaq listing compliance extension. The company implemented a 15-for-1 reverse stock split effective July 25, 2025.
IMUNON (NASDAQ: IMNN) has announced a significant milestone in its clinical development program with the first patient dosed in the pivotal Phase 3 OVATION 3 Study of IMNN-001 for newly diagnosed advanced ovarian cancer. The study evaluates IMNN-001 in combination with standard chemotherapy versus standard care alone.
The trial will assess IMNN-001 (100 mg/m2) administered intraperitoneally weekly alongside neoadjuvant and adjuvant chemotherapy. The randomized 1:1 study focuses on women with stage 3C or 4 advanced ovarian cancer, with overall survival as the primary endpoint. The development follows successful Phase 2 OVATION 2 Study results presented at ASCO 2025, which demonstrated meaningful improvements in survival outcomes and favorable safety profiles.
IMUNON (NASDAQ: IMNN), a clinical-stage biotechnology company, has scheduled its second quarter 2025 financial results conference call for August 5, 2025, at 11:00 a.m. ET. The company will discuss Q2 2025 financial performance and provide updates on IMNN-001, their DNA-based interleukin-12 immunotherapy currently in Phase 3 clinical trials for advanced ovarian cancer.
Investors can access the call via toll-free numbers or join through a live webcast. A replay will be available until August 19, 2025, through multiple channels including toll-free numbers and a 90-day audio replay on the company's website.